Clinical Research Centre
Hospital Wanita dan Kanak-Kanak Sabah
Likas, Sabah
WhoWe Are
Clinical Research Centre Sabah Women and Children Hospital (CRC HWKKS) was established as part of the Network of Clinical Research Centres of the Ministry of Health (MOH) on 17 February 2011. It is headed by Dr Flora Chong Li Tze and the deputy is Dr Lim Song Hai. In CRC HWKKS, we aim to promote, support and conduct quality and ethical clinical research to improve patients’ outcome in HWKKS. As a team, we undertake clinical research and provide research-related administrative services and training courses to bridge the gap and explore the future direction of research. Our research focus: Biomedical, Clinical, Epidemiology and Behavioral Science Disease Area: Oncology, Gynecology, Pediatrics, Pathology, TCM, Nuclear Medicine, Radiology and Pharmacy
OurTeam
| NMRR-24-00271-ZQE | Systematic Review on the Effect of Traditional and Complementary Medicine on the Quality of Life of Cancer Patients |
| NMRR-22-00597-U2F | Study of PembrolIzumab (MK-3475) Plus Platinum and GEmcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER) |
| NMRR-23-01688-NO9 | Development And Validation of Prognostic Mortality Scoring Tool Among Hospitalised COVID-19 Patients with Thromboembolic Complications (PROG-M COVID-19 Score) |
| NMRR-22-01338-NBF | Multicentre retrospective clinical epidemiological study of female breast cancer in a multi-ethnic Malaysian setting (EPI-CAN) |
| NMRR-19-3974-52082 | A Retrospective Cohort Study on The Treatment Outcome of Paediatric Medulloblastoma in Sabah Women and Children Hospital (SWACH) |
| NMRR-23-01008-V4J | CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence |
| NMRR-23-01854-V44 | SAFFRON: A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated MET Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON) |
| NMRR-23-00528-1QF | ASCENT 03: A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1 (ASCENT 03) |
| NMRR-23-00642-NZG | ASCENT 04: A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1 (ASCENT 04) |
| NMRR-21-1438-58702 | KRYSTAL-10: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy |
| NMRR-23-03325-QCO | EVOPAR: A Randomized, 2-cohort, Double blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physician's Choice New Hormonal Agents in Patients with HRRm and non-HRRM Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01) |
List of Publications associated with CRC HWKKS
- Obstructed Hemivagina Ipsilateral Renal Agenesis (OHVIRA) Syndrome – A Retrospective COHORT Analysis On The Sabah Population
- Leek Mei Lim, Lavitha Sivapatham, Audrey Shuk Lan Chong, Ana Vetriana Abd Wahab
- Financial Toxicity Following Cancer in a Middle-Income Country with a Pluralistic Health System:Validation of the COST Questionnaire
- Veni V. Sakti, Mahmoud Danaee, Cheng-Har Yip, Ros S. A. Bustamam, Marniza Saad, Gin Gin Gan, Jerome Tan, Yueh Ni Lim, Flora L.T. Chong, Murallitharan Munisamy, Farahida Mohd Farid, Boon Lui Sew, Yek-Ching Kong, Nishalini Muniandy, Nirmala Bhoo-Pathy
- The Effectiveness Of Epilepsy Educational Intervention Using Computer Game-Based Epilepsy Educational Program (Epigame) Among Malaysian Children With Epilepsy: A Prospective Cohort Study
- Choong Yi Fong, Peiyi Low, Kher Hui Ng, Hock Sin Heng, Audrey Shuk Lan Chong, Lai Choo Ong, Yusma Liyana Md Yusof, Azirah Adnan, Limin Li, Wei Kang Lim
- Factors Associated With Outcomes Of Severe Acute Necrotizing Encephalopathy: A Multicentre Experience In Malaysia
- Vanessa Wan Mun Lee, Teik Beng Khoo, Chee Ming The, Hock Sin Heng, Limin Li, Yusma Lyana Md Yusof, Nor Azni Yahaya, Sangita Dharshini, Sau Wei Wong, Tai Nickson, ANE Malaysia Outcome Study Group
- The Association Between Maternal Short Stature And Neonatal Intensive Care Unit Admission: A Longitudinal Study In Sabah
- Ehab Helmy, Helen Benedict Lesimbang, M Tanveer Hossain Parash, Soon Ruey, Nurhidayah Binti Kamarudin, Ong Teck Siong, Teoh Jie Sheng, Khairul Sabrin Bin Ahmad, Syaza Nadia Binti Saman, Kueh Bing Ling
- Malaysian Specialists’ Involvement In Research: Attitudes, Barriers And Facilitators
- Bing-Ling Kueh, Juhanah Gimbo, Katinah Majunkob, Fatrina Simon, Ammar Rafidah Saptu, Mui-Nyuk Wong
Upcoming Activities
CRC Hospital Wanita dan Kanak-Kanak Sabah, Likas, Sabah
Clinical Research Centre,
7th Floor,
Nuclear Medicine & Radiotherapy Centre,
Sabah Women & Children Hosp. (Likas Hospital),
88996 Kota Kinabalu, Sabah, Malaysia.
Email: crclikas@gmail.com
Phone number: +6088 522 600 ext. 2272
